AstraZeneca PLC Settles U.S. Pricing Lawsuit for $103 Million

Published: Jun 21, 2010

Reuters -- AstraZeneca PLC (AZN.L) has agreed to pay $103 million to settle U.S. litigation involving claims the drugmaker inflated prices for its Zoladex cancer drug and Pulmicort Respules asthma medicine.

Back to news